NOVO-NORDISK AS (NVO)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-05
$40.30-4.46%
Close 2026-11-05 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-05
QuarterlyIQ Insights · NVO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -7.4% |
| Our one-year growth estimate | diamond | Not available |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 11 industry peers · Company calendar date is not available
Why it matters: If revenue growth picks up, it could signal a positive trend for the sector.
Supportive ifQ3 revenue growth exceeds 9% year over year.
Worry ifQ3 revenue growth remains below 9% year over year.
Why it matters: A return to higher revenue growth would signal a stronger sector recovery. This could improve investor confidence in Novo Nordisk.
Supportive ifRevenue growth speeds up to 12% year over year.
Worry ifRevenue growth remains below 9% year over year.
Why it matters: A drop below median revenue growth would signal a slowdown in the sector's expansion. This could impact investor confidence in NOVO-NORDISK's growth prospects.
Worry ifRevenue growth falls below the median growth rate for the health care sector.
Less concerning ifRevenue growth remains above the median growth rate for the health care sector.
Why it matters: If revenue growth picks up, it could signal a stronger market for Novo Nordisk's products.
Supportive ifHealth care sector revenue growth speeds up again. It is now close to 12% year over year.
Worry ifRevenue growth stays below 9% year over year.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$124 on $10,000 · ±1.2% | How much price usually moves either way. |
| Bad day | $327 loss on $10,000 · 3.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,367 loss on $10,000 · 43.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If the health care sector outperforms, it could lift NOVO-NORDISK shares. Strong sector performance often helps individual stocks.
Supportive ifHealth care sector shows a relative performance increase of more than 5% over the next 60 days.
Worry ifHealth care sector underperforms by more than 5% over the next 60 days.
Why it matters: If revenue growth speeds up, it may show a stronger market for Novo Nordisk.
Supportive ifSector revenue growth is speeding up to 12% each year.
Worry ifSector revenue growth is slowing down to below 8% each year.
Why it matters: The earnings report will provide insights into revenue and profit trends for NVO.
Watch forEarnings report shows stronger than expected revenue and profit growth.
Also watch forEarnings report reveals weaker than expected revenue and profit growth.
Why it matters: Earnings results will provide insights into how Novo Nordisk is performing compared to peers. This can impact stock sentiment.
Watch forEarnings beat expectations with growth in key product lines.
Also watch forEarnings miss expectations or show declines in key product lines.